Results overview: Found 3 records in 0.02 seconds.
Articles, 3 records found
Articles 3 records found  
1.
9 p, 906.5 KB Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice : results from the NEUF study / Boissel, Nicolas (Saint-Louis Hospital. Division of Hematology, EA3518 Saint-Louis Institute for Research) ; Chiaretti, Sabina ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ; Papayannidis, Cristina (Institute of Hematology "Seràgnoli". IRCCS, Azienda Ospedaliero Universitaria di Bologna) ; Ribera, Jose-Maria (Universitat Autònoma de Barcelona. Departament de Medicina) ; Bassan, Renato (Complex Operative Unit of Hematology, dell'Angelo Hospital and Santissimi Giovanni and Paolo Hospital, Mestre and Venice, Venezia-Mestre, Italy) ; Sokolov, Andrey N. (National Research Center for Hematology, Moscow) ; Alam, Naufil (Amgen Ltd, Uxbridge, United Kingdom) ; Brescianini, Alessandra (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Pezzani, Isabella (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Kreuzbauer, Georg (Amgen (Europe) GmbH, Rotkreuz, Switzerland) ; Zugmaier, Gerhard (Amgen Research (Munich) GmbH, Munich, Germany) ; Foà, Robin ("Sapienza" University. Hematology Department of Translational and Precision Medicine) ; Rambaldi, Alessandro (University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII. Department of Oncology and Haematology)
This retrospective observational study (NEUF) included adult patients with B-cell acute lymphoblastic leukemia (B-cell ALL) who had received blinatumomab for the treatment of minimal residual disease-positive (MRD+) or relapsed/refractory (R/R) B-cell ALL via an expanded access program (EAP). [...]
2023 - 10.1038/s41408-022-00766-7
Blood Cancer Journal, Vol. 13 (january 2023)  
2.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
3.
7 p, 444.1 KB Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia / Gökbuget, N. (Goethe University. University Hospital Frankfurt) ; Kelsh, M. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Chia, V. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Advani, Anjali (Cleveland Clinic (Estats Units d'Amèrica)) ; Bassan, Renato (Ospedale dell'Angelo (Venècia, Itàlia)) ; Dombret, Hervé (Hôpital Saint-Louis (Paris, França)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Fielding, A. K. (UCL Cancer Institute (Londres, Regne Unit)) ; Giebel, S. (Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology (Polònia)) ; Haddad, V. (Amgen Ltd. (Uxbridge, Regne Unit)) ; Hoelzer, Dieter (Goethe University. University Hospital Frankfurt) ; Holland, C. (Amgen Ltd. (Rockville, Estats Units d'Amèrica)) ; Ifrah, N. (Centre Hospitalier Universitaire (Angers, França)) ; Katz, A. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Maniar, T. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Martinelli, Giovanni (Policlinico Sant'Orsola-Malpighi (Bolònia, Itàlia)) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; O'Brien, Susan (University of Texas MD Anderson Cancer Center (Houston, Texas)) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rowe, J. M. (Rambam Medical Center) ; Stein, Anthony (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Topp, M. (Universitätsklinikum Würzburg (Alemanya)) ; Wadleigh, M. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Kantarjian, H. (University of Texas MD Anderson Cancer Center (Houston, Texas))
We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. [...]
2016 - 10.1038/bcj.2016.84
Blood Cancer Journal, Vol. 6, Núm. 9 (September 2016) , p. e473  

See also: similar author names
1 Bassan, R
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.